The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients
- 1 January 2004
- journal article
- Published by Elsevier BV in Gastroenterology
- Vol. 126 (1), 19-31
- https://doi.org/10.1053/j.gastro.2003.10.047
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor AntagonistAnnals of Internal Medicine, 2003
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's diseaseThe American Journal of Gastroenterology, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Infliximab Treatment for Crohn's Disease: One-Year Experience in a Dutch Academic HospitalInflammatory Bowel Diseases, 2002
- Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patientsThe American Journal of Gastroenterology, 2001
- Infliximab in Crohn's Disease: First Anniversary Clinical ExperienceAmerican Journal Of Gastroenterology, 2000
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Crohn's disease in Olmsted County, Minnesota, 1940–1993: Incidence, prevalence, and survivalGastroenterology, 1998
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997